An anti-amyloid drug for blindness
A small molecule drug candidate for Alzheimer’s treatment
What Does 2025 Hold For Biopharma? Part 6: Therapeutic Area Advances
Scrip Asks…What Does 2024 Hold For Biopharma? Part 2: The Funding Environment, M&A And Partnering
Kleine Moleküle mit Großer Wirkung
Galimedix targeting misfolded amyloid in retinal diseasee
Alzheimer’s disease and age-related macular degeneration – how are they linked and what are the treatments?